In this episode, Kyle interviews Geoff Bathje, Ph.D.: licensed psychologist, researcher, former Full Professor, and co-founder of Sana Healing Collective, a Chicago-based non-profit focusing on ketamine-assisted therapy and psychedelic integration.

He talks about what he feels is one of the largest factors in our mental health crisis: the individualistic and neoliberal lens Western culture has placed on mental health and how it neglects the massive systemic and relational factors that are affecting us all. He digs into how we got so alienated and how psychedelics and non-ordinary states of consciousness can not only help us think critically and solve problems, but also move us out of this individualistic framework of healing and more into a collective one. How do we use psychedelics to fix our relationships and find our community?

He discusses:

• The challenge of knowing when to work for relationships and when to just end them, especially in the afterglow of a big experience
• Group ketamine experience vs. individual, how groups can help facilitators find patterns, and how ketamine works with somatic therapy
• His paper, “Psychedelic integration: An analysis of the concept and its practice” and his visual model of integration showing the different domains of our personal experience
• What he thinks will happen next in drug development: Will therapy be left out after Lykos’ failure with MDMA?
• The importance of moving beyond aggressive criticism and moving into world building

and more! 

For links, head to the show notes page. 

In this episode, Joe interviews Thomas Feegel: co-founder of Beond Ibogaine, an ibogaine treatment and research facility in Cancún, Mexico.

When Feegel first heard of ibogaine 16 years ago, he found that people were having great success, but nobody could recommend where to go for treatment. So he worked to create what was needed: a combination of a hospital, mental health treatment facility, retreat center, and resort, with the proper infrastructure in place, employees with ICU experience, exhaustive HIPAA-compliant admission criteria, regular data collection, and a major focus on safety.

Addressing the recent Rolling Stone article about the tragic death of a patient at Beond in 2022 (interestingly, 2 days after his initial dose), he discusses what he feels was inaccurate, largely related to what could be perceived as a suggestion that there wasn’t enough screening or that corners were cut. With no official reason given for the patient’s death, it brings into question just how safe one can be, especially with people whose bodies and hearts have been through so much. How much hidden harm is created by the stress of PTSD and addiction?

He discusses:

• The complexity of journalism and drawing conclusions from limited information
• The limitations of conventional addiction treatments and the sad numbers around how many people stick with rehab
• The importance of collecting as much data as possible about each patient, at regular intervals, prior to, during, and after the experience
• The need for a regulating group to create standards around admission and administration procedures for ibogaine

and more! 

We’re releasing this episode on Veterans Day because Beond’s program was co-developed by veterans, military medical personnel, and active-duty law enforcement officers who have seen how much ibogaine can help. If you know a vet who is struggling, be sure to let them know what's possible with psychedelic therapy. 

For links, head to the show notes page. 

In this episode, David interviews Floris Wolswijk: senior project manager at Delphi; co-founder of FLO coaching; and founder of Blossom, an online informational hub collecting psychedelic courses, trials, companies, and over 2000 categorized research articles.

When Wolswijk began Blossom, he was barely able to fill a weekly newsletter, and now he’s adding a new study nearly every day, perfectly illustrating the exponential growth in psychedelic research. He talks about why so much research is happening (and why more isn’t), the trends he’s seen, the benefit in research changing people’s minds, and what he hopes for in the future. What can the research community learn from existing real world evidence, and how can retreat centers and underground communities contribute?

He also discusses:

• What culture is like in the Netherlands, where psilocybin truffles are legal
• Drug development and the possibilities of adjusting existing molecules
• What we can learn from the Lykos and FDA situation
• The economics of psychedelics and how insurance will likely be the next big conversation
• His work with FLO coaching, and how coaching, acceptance and commitment therapy, and psilocybin can work together

and more! 

For links, head to the show notes page. 

In this episode, Joe interviews Jessica Tracy: head of sales & partnerships at Enthea, a company that works with employers, unions, and employee assistance programs to be able to offer ketamine-assisted therapy (and psilocybin where it’s legal) to employees.

She talks about her path to psychedelics and how the shifts in her life led her to want to help others, finding Enthea and using her 15 years of experience in healthcare to make an immediate difference. She explains how the process works for an employee of a company Enthea works with, and the importance of evidence-based medical policy and rigorous screening to make sure people are getting the best intervention possible. One of Enthea’s largest clients is Dr. Bronner’s, who reported incredible improvements after employees used the benefit, with a 65% improvement in depression scores and an 86% improvement in PTSD.

She also discusses:

• How psychedelics bring awareness to what we need to work on
• Less-discussed treatment modalities, like electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and stellate ganglion block (SGB)
• The inefficiency of traditional talk therapy: 50% of people only see really good benefits after 20 sessions
• The importance of viewing mental health as individualized care: What else can we offer to people who haven’t been helped by traditional methods?
• The research that she wants to see, like measures in how present or productive people are before and after experiences

and more!

For links, head to the show notes page. 

In this episode, Joe and Kyle finally meet up again for the first episode of Psychedelics Lately: the updated version of the much-missed Psychedelics Weekly, where they’ll meet each month to talk about the most interesting stories in psychedelics.

The main story this month is the fate of Massachusetts’ Question 4: Regulated Access to Psychedelic Substances Initiative (The Natural Psychedelic Substances Act). They discuss what they like about the bill, its opposition, and its support, including actress Eliza Dushku Palandjian, who went from a diagnosis of PTSD and an in-the-psychedelic-closet underground experience to becoming a very public, soon-to-be certified psychedelic facilitator. If you live in Massachusetts, make sure to read about the bill and get out and vote this Tuesday (or now, if you’re registered for early voting).

They also discuss:

• Joe’s recent east coast travels to Harvard and the PhilaDelic conference
• Alfred North Whitehead and Process Philosophy
• The Psychedelics and Pain Association, and Court Wing’s involvement in the first published case report of complex regional pain syndrome being treated with psilocybin
• The scientific community needing to embrace more experientially-based approaches and practices
• The challenge of making meaning out of the mystical

and more! 

For links, head to the show notes page. 

In this episode, Joe interviews Dr. Peter Sjöstedt-Hughes: philosopher, lecturer at the University of Exeter, co-director of the Breaking Convention conference, and author who most recently co-edited Philosophy and Psychedelics: Frameworks for Exceptional Experience.

He discusses how the work of William James and an early psilocybin experience led him to an interest in philosophy and psychedelics, and he dives deep into several philosophical concepts: panpsychism, pantheism, ethical pluralism, teleology, process theology, Whitehead’s fallacy of misplaced concreteness, and more. He believes that science has lost touch with metaphysics – the branch of philosophy that examines the basic structure of reality – and that studying metaphysics will lead to more beneficial experiences with the non-ordinary: If you can understand and frame the experience, you’ll have a much better chance of being able to integrate its lessons.

He discusses:

• The complexity of ethics and the need to ask more philosophical questions
• His book, Neo-Nihilism, which argued that there are no shared objective morals
• The West’s’ obsession with scientism and believing only what can be reducible to matter: Is science honest if it ignores the ineffable?
• The connections between philosophical frameworks and religion: Would studying comparative religion help us better understand each other?
• The need for more experiential research

and more! 

Sjöstedt-Hughes is the co-lead on Exeter’s 12-month postgraduate certificate course, “Psychedelics: Mind, Medicine, and Culture,” and is finalizing his next book, a manual on psychedelics and metaphysics.

For links, head to the show notes page.

In this episode, Joe interviews 4 members of the Penn Psychedelics Collaborative: Co-Founder, Taylor Andrews Flatt, PMHNP; Associate Director, Victor Pablo Acero, Ph.D.; Professor in Fine Arts and Co-Director of the Weitzman School of Design, Jackie Tileston; and Executive Director and Director of the Penn Program for Mindfulness, Michael Baime, MD.

Recorded earlier this month at the PhilaDelic conference – one of the primary initiatives of the PPC – they discuss their paths to psychedelics and why this transdisciplinary collection of faculty, researchers, and clinicians at the University of Pennsylvania was so necessary. Viewing psychedelics from different perspectives (Flatt from nursing, Acero from bioengineering, Tileston from the art and mysticism side of things, and Baime from a more mindfulness point of view), their group is a case study in collaboration – a place where connections can be catalyzed and shared goals can be addressed from different angles. How far can we go when different groups start working together?

They discuss:

• The concept of psychedelics not just being used to treat conditions, but to make us healthier
• Psychedelic art and the idea of the art itself being psychoactive rather than just representations of trips
• The work of David Glowacki and bringing about non-ordinary states of consciousness through VR
• Research into salvia being used to alleviate stroke symptoms
• How a lack of funding can really create focus

and more! 

For links, head to the show notes page.

In this episode, Joe interviews two people on the frontlines of the campaign for Massachusetts' Question 4: The Natural Psychedelic Substances Act: Graham Moore and Community Engagement Director, Jamie Morey.

They discuss the specifics of the initiative, listed on the ballot as the “Limited Legalization and Regulation of Certain Natural Psychedelic Substances,” including the removal of criminal penalties for limited personal use, and the establishment of a regulatory agency that will provide therapeutic access to any of five natural psychedelics (psilocybin, psilocin, DMT, mescaline, and ibogaine). They tell their stories of how they discovered the power of psychedelics, and discuss the work they’re doing, educating a fairly interested – but still very hesitant – public about the bill and the importance of it passing this November.

They talk about:

• The significance of this happening in Massachusetts, especially with the amount of biomedical research happening in Boston
• The story of a member of Baystaters creating a fraudulent persona in a veterans advocacy group to fight against legalization efforts
• The challenge of getting people to publicly support initiatives that deal with illegal substances
• The power of small steps in legislation: Before this bill, MA had the most local measures in the U.S.
• How data collection should be handled at service centers

and more! 

If you live in Massachusetts, learn about the bill here, and make sure to get out and cast your vote in November. 

For links, head to the show notes page. 

In this episode, Joe interviews Diana Quinn, ND: naturopathic doctor, healing justice practitioner, and director of clinical education at the Naropa Center for Psychedelic Studies, where she directs their Psilocybin Facilitator Training certificate program.

She discusses her path from anthropology to naturopathy, and eventually to psychedelics and activism, finding a framework for psychedelic education grounded in healing justice, which recognizes the impact of collective trauma on all of us, seeks to reclaim lost or stolen models of healing, focuses on equity and accessibility, and brings an anti-oppression lens to training programs to give students a greater capacity for culturally responsive care. She encourages seeing things from an anti-capitalist viewpoint, and recognizes the huge clash between using such powerful and mystical medicines inside structures so embedded with problematic human qualities. How can you build inside of these Western systems without being affected by that capitalist energy?

She discusses:

• The importance of respecting plants from other cultures – that no healing or consciousness expansion is justifiable when it threatens an entire species
• The challenge of integrating the weirdest parts of non-ordinary states into education: How does a Western framework come to terms with the ineffable?
• How colonialism and the culture born from it has hurt us all
• The importance of finding your own lineage and what is sacred to you
• The work of Rick Tarnas and the amazing patterns we can find in astrology

and more! 

For links, head to the show notes page. 

In this episode, Joe interviews Rick Doblin, Ph.D.: founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), and former board member at Lykos Therapeutics, MAPS’ public benefit subsidiary.

Doblin tells his side of the story: that the FDA’s concerns with double blinding not working had been fully addressed ahead of time, that they had negotiated agreements that were no longer agreed to when new FDA employees came on board, that there was a lot of confusion from going back and forth with the FDA on how Phase 3 studies should be designed, and more. He believes that Lykos made a massive mistake in assuming that provable science was more important than public opinion, and that ignoring critics who were saying whatever they wanted caused them to lose control of the narrative – which clearly influenced the advisory committee. While Lykos figures out their next steps with the FDA, MAPS is focusing their attention on what they feel is most important in light of this ruling: better public education and drug policy.

He talks about:

• How there’s a bias at the FDA to be harsh: Does automatically saying no just make it look like you’re being rigorous?
• The work of the Dutch government in researching MDMA, and Lykos’ odd decision to not highlight any of it
• Massachusetts’ Legalization and Regulation of Psychedelic Substances initiative, and the huge opportunity for progress at the local level
• Why federal agents at Burning Man work so hard to give tickets to attendees for smoking cannabis
• Why sharing stories of your positive experiences with psychedelics is so important

and more! 

MAPS has announced that 2025’s Psychedelic Science conference will be in Denver, June 16-20, and will have experiential opportunities before and after. 

For links, head to the show notes page. 

In this episode, Kyle interviews Gabriela Galindo: program coordinator of FLOWS (Foundations for Leaders Organizing for Water and Sustainability), an organization working towards social and environmental justice, ecosystem restoration, community building, and the preservation and protection of Indigenous medicines.

She discusses her entry point to psychedelics and how she got involved with Colorado’s Natural Medicine Health Act (Prop 122) when she saw a complete absence of Indigenous representation in the legislature. The narrative that we all have a right to healing and that these medicines belong to everyone is pretty common today, but Galindo argues that this is not fair: that each plant has its own history, and that each is protected by its own culture. Shouldn’t the communities that have stewarded these medicines for centuries have a say in whether their medicine is going to be shared and legislated at the state level? Shouldn’t they have the ability to consent to these new proposals?

She talks about:

• Why she likes using ‘movement’ instead of ‘renaissance’ when discussing our psychedelic culture
• What we could learn from Indigenous people’s harmony with nature as we face an ongoing climate crisis
• The balancing act of pleasing everyone: Would decriminalization be as supported if Indigenous communities wanted to keep some of these substances criminalized for the protection of their culture and their ecosystems?
• How psychedelic communities should evolve to include community work into their routines: What do local communities need and how can you help?
• The importance of knowing when to step aside and truly center a community voice

and more! 

For links, head to the show notes page.